Human Longevity, Inc. (HLI), based in San Francisco, is a global leader since 2013 in advancing precision medicine in the pursuit of healthy aging, often referred to as longevity medicine. HLI is committed to accelerating living to 100+ by revolutionizing the landscape of the current system of “sickcare” to true “healthcare.”
Founded by Dr. J. Craig Venter, one of the pioneers of the human genome sequencing effort, HLI builds on his vision for a longer, healthier life and the democratization of genomics to revolutionize the way we evade “avoidable disease” and stay healthy longer. The company is recognized as a leader in the rapidly expanding industry of longevity medicine due to its deep expertise in genomics and other fields of precision medicine such as imaging, and its unmatched, longitudinal patient dataset built on decades of research in the field.
The tech-enabled company has proprietary tools for the detection of gene-disease associations, including HLI’s artificial intelligence health risk and recommendation platform, and provides its clients with pre-symptomatic diagnosis and customized treatments, preempting disease at a very early stage and maximizing health outcomes. In short, HLI is transforming healthcare from a reactive practice to one that is predictive, proactive, and preventative, which not only enhances the quality of lives of individuals but improves the efficiency and efficacy of the entire healthcare system.
The interest and investment in longevity and anti-aging therapies have been steadily increasing in the US and internationally, due to advancements in technology, increased awareness, and a growing aging population. By 2028, the global longevity market is expected to reach close to USD 183Bn. TVM Capital Healthcare’s investment in HLI will help strengthen the company’s position globally as the most data-backed longevity practice and help establish its foothold in markets, like Saudi Arabia and SEA, that see the potential of its approach to preventive medicine in achieving national healthcare goals as well as the huge impact it will have on changing the cost of medicine. For example, KSA’s Vision 2030 has the ambitious target of increasing average life expectancy from 74 to 80 years, and Southeast Asian markets have government support for increasing “healthspan” and providing a healthcare system where a greater majority of the population are healthy and disease-free, particularly as demographics shift towards an ageing population.
TVM Capital Healthcare will actively add value by leveraging its extensive international Diagnostic and Biotechnology network as well as its network of global advisors in order to optimize operations and marketing efforts, and support HLI’s global expansion opportunities, particularly in KSA and Southeast Asia.
Impact
Access
HLI is a health firm where the goal is to stay ahead of aging and illness. The platform will save millions of lives and significantly reduce healthcare costs in the future.
According to the WHO, every country in the world is experiencing growth in both the size and the proportion of their elder population. HLI’s technologies and treatments create a longer, healthier life, which will reduce the overall burden on the healthcare sector.
Quality
By continually analyzing health data from its clients, the company seeks to identify potential health issues early, enabling targeted interventions that can extend not only lifespan but also the period of healthy living, or healthspan.
The company has deep expertise in genomics and an unmatched, longitudinal patient dataset built on decades of research in the field.
Innovation
At the core of HLI’s offering is the 100+ Longevity Care program which is designed to detect early signs of age-related diseases and provide interventions using a variety of tools such as genome sequencing, advanced imaging techniques like whole-body and brain MRIs, comprehensive cardiac evaluations, body composition analyses, advanced blood biomarkers, and wearable devices.
This combination of data and technology enables a highly personalized approach to health management, with the goal of reducing biological age and preventing disease.
Future Growth Prospects
Beyond its work with its clients, HLI is also focused on conducting longevity research, which will help democratize genomics and revolutionize the way more people, including those in underserved communities, evade “avoidable disease” and stay healthy longer.
A healthier population also creates a more productive workforce, which is critical to a country’s economic success.
